Phaseline

Targets › MEN1

MEN1 (Menin): drug programs, companies and trials

7 programs from 7 companies in 34 trials: 24 Phase 1, 5 Phase 2, 5 Phase 3; Oncology, Metabolic and endocrine; next expected readout Dec 2026.

Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. (UniProt, O00255)

Open in Phaseline: the race on MEN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kura OncologyZiftomenib (KO-539)
Menin inhibitor
MEN1Phase 3Acute Myeloid Leukemia (AML); AML; Advanced Malignant Neoplasm; Gastrointestinal Stromal Tumor (GIST) …Dec 2026
Syndax Pharmaceuticalsrevumenib
Menin/Histone-lysine N-methyltransferase MLL inhibitor; Menin inhibitor
MEN1, KMT2APhase 3Acute Myeloid Leukemias; Acute Myeloid Leukemia; Acute Myeloid Leukemia, Adult; Recurrent Acute Leukemia of Ambiguous Lineage …Feb 2027
Johnson & Johnson (Janssen)Bleximenib
Menin inhibitor
MEN1Phase 3Leukemia, Myeloid, Acute; Acute Leukemia; Acute Myeloid LeukemiaJun 2027
M.D. Anderson Cancer CenterRevumenib Sesquifumarate (SNDX-5613)
Menin/Histone-lysine N-methyltransferase MLL inhibitor
MEN1, KMT2APhase 2Leukemia; Acute Myeloid LeukemiaDec 2026
Biomea Fusionicovamenib 100 mg
Menin inhibitor
MEN1Phase 2Type 2 DiabetesMar 2027
Uma BorateZiftomenib
Menin inhibitor
MEN1Phase 2Acute Myeloid LeukemiaDec 2027
Sumitomo Pharma AmericaEnzomenib (DSP-5336)
Menin inhibitor
MEN1Phase 1Leukemia, Myeloid, AcuteJun 2027

Conditions

Acute Myeloid Leukemia (12) Leukemia, Myeloid, Acute (3) Type 2 Diabetes (2) Acute Myeloid Leukemias (2) Acute Leukemia (2) Leukemia (2) Acute Myeloid Leukemia (AML) (1) AML (1) Advanced Malignant Neoplasm (1) Gastrointestinal Stromal Tumor (GIST) (1) KMT2A-rearranged (1) Refractory Acute Leukemia (1)

Modalities

small molecule (5), mixed (2)

Companies

Biomea Fusion (1) Kura Oncology (1) Syndax Pharmaceuticals (1) M.D. Anderson Cancer Center (1) Johnson & Johnson (Janssen) (1) Sumitomo Pharma America (1) Uma Borate (1)

Related targets

KMT2A (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.